Stanley Laman Group, Ltd. Affimed N.V. Transaction History

Stanley Laman Group, Ltd.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2018 Oct 30, 2018	SELL	$1.45 - $6.15 $88,006 - $373,268	-60,694 Closed	0 $0
Q2 2018 Aug 09, 2018	BUY	$1.65 - $2.5 $100,145 - $151,735	60,694 New	60,694 $100,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Stanley Laman Group, Ltd., based on Form 13F filings with the SEC.

Stay updated on Stanley Laman Group, Ltd. with notifications on news.